Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Transarterial Chemoembolization: A Prospective Study Utilizing Twin Internally Cooled-Perfusion Electrodes [0.03%]
经导管动脉化疗栓塞术后复发性肝细胞癌的射频消融：一项利用双内冷灌注电极增强射频消融的前瞻性研究
Sungjun Hwang,Jae Hyun Kim,Sae-Jin Park et al.
Sungjun Hwang et al.
Background: Radiofrequency ablation (RFA) is widely employed for managing recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE). However, local tumor progression (LTP) after treatment r...
Microwave ablation versus liver resection for patients with hepatocellular carcinomas [0.03%]
微波消融与肝脏切除治疗肝细胞癌患者的疗效比较
Hyundam Gu,Yeonjoo Seo,Dong Jin Chung et al.
Hyundam Gu et al.
Backgrounds/aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared th...
Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma [0.03%]
L-精氨酸和精氨琥珀酸合成酶1在诱导肝癌细胞凋亡中的协同作用
Jin Sun Kim,Won-Mook Choi,Ha-Il Kim et al.
Jin Sun Kim et al.
Background/aims: Hepatocellular carcinoma (HCC) is a malignant cancer with an increasing incidence worldwide. Although numerous efforts have been made to identify effective therapies for HCC, current strategies have limit...
Molecular and immune landscape of hepatocellular carcinoma for therapeutic development [0.03%]
肝细胞癌的分子和免疫图谱及其靶向治疗开发
Hiroyuki Suzuki,Sumit Mishra,Subhojit Paul et al.
Hiroyuki Suzuki et al.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with an estimated 750,000 deaths in 2022. Recent emergence of molecular targeted agents (MTAs) and immune checkpoint inhibitors (ICIs) and their combin...
Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea [0.03%]
韩国肝细胞癌流行病学、病因和治疗模式的演变趋势
Soo Young Hwang,Ju Dong Yang
Soo Young Hwang
Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report [0.03%]
接受阿特珠单抗-贝伐珠单抗治疗的门静脉瘤栓肝细胞癌患者在停药后的持久完全缓解：首例报道
Pramod Kumar,Pradeep Krishna,Rohit Maidur et al.
Pramod Kumar et al.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may expe...
Case Reports
Journal of liver cancer. 2024 Nov 5. DOI:10.17998/jlc.2024.09.26 2024
Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future [0.03%]
肝细胞癌降期治疗的多学科策略：现状和未来方向
Sang-Youn Hwang,Hyunwook Choi,Wan Jeon et al.
Sang-Youn Hwang et al.
Downstaging of hepatocellular carcinoma (HCC) is typically defined as the reduction in size or number of viable tumors through locoregional therapy (LRT), aiming to meet the established criteria for liver transplantation (LT). According to ...
Congratulatory remarks [0.03%]
祝贺词
Kyung Sik Kim
Kyung Sik Kim
Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association [0.03%]
2024年韩国肝癌协会局部消融治疗肝细胞癌专家共识实用建议
Seungchul Han,Pil Soo Sung,Soo Young Park et al.
Seungchul Han et al.
Local ablation for hepatocellular carcinoma (HCC), a non-surgical option that directly targets and destroys tumor cells, has advanced significantly since the 1990s. Therapies with different energy sources, such as radiofrequency ablation, m...